Tumor cells produce short protein fragments (peptides) or mutated proteins, as a result of the high number of mutations that occur in tumor cell DNA. Since these mutations are absent from the normal human genome, the resultant tumor-specific neoantigens (TSNA) can be used as unique identifiers or markers of a specific tumor cell and pose exciting opportunities in personalized medicines for cancer therapies, and other diseases.
Ex-vivo cell therapy
In multiple cell therapy trials, stem cells are isolated from patients and exposed ex vivo to several agents, including peptides, which induce ie their differentiation while growing in the lab. The cells are then reinjected in the patient to cure a cell-specific disease.
There is great interest in developing cell therapies using peptide neoantigens to prime dendritic cells (DCs) to target specific tumors for destruction by the immune system. DCs are pulsed ex vivo with neoantigens then reintroduced back into the patient in order to prevent tumor cells from suppressing dendritic cell functions and allowing for the enrichment of DC’s to elicit a stronger T-cell response.
Pre-clinical animal testing
To facilitate consistency in pharmacokinetic and toxicity studies, GMP grade peptides should be considered for utilization in pre-clinical animal studies.
IVD companies or Clinical laboratories pursuing the development of in vitro diagnostic tests for the detection of molecules and analytes in biological samples, should consider using GMP grade peptide ASR’s.
GMP peptides can also be used in such in vivo diagnostic applications as PET scans. Peptides used for in vivo diagnostic imaging are typically modified to improve their biological half-life, and to accommodate downstream radiolabeling. AnaSpec is specialized in both of these types of custom modifications to improve peptide metabolic stability, including cyclizations, D-amino acids, PEGylations, and peptide conjugations to chelators such as DOTA for downstream radiolabeling.
*AnaSpec does not offer radiolabeling services
QC Controls & Standards for biopharmaceuticals & API's
Calibration standards for LC-MS/MS, 2-D electrophoresis for analyzing performance of mass spectrometers, and for characterizing proteins including enzymatic activity.
Peptides are now regularly used in the cosmetics and anti-ageing market.
The skin care market is projected to increase over the next few years owed to the demand for new options in skin care cosmetics to improve skin tone, fine lines and wrinkles, texture, and hyperpigmentation, in a non-invasive manner.
Peptides will remain a key ingredient in cosmeceutical products, as their roles in collagen production and in skin protection (skin antimicrobial peptides), are further studied. We expect to see such knowledge applied to the development of new skin care maintenance and repair alternatives.
Biomaterial Peptide Coatings
A major issue with implanted medical devices is the occurrence of biomaterial-associated infections (BAI). These infections develop when microbial biofilms form on a device surface. As conventional antibiotic treatments cannot be localized onto a device, they are not an effective solution. A potential answer is the application of GMP antimicrobial peptide coatings applied onto the medical device surface in order to target their effects.
BioPharmaceutical manufacturing materials & precursors
GMP peptides synthesized at AnaSpec can be incorporated as starting materials in the production of biopharmaceuticals.
One example is the conjugation of peptide antigen to sepharose beads to act as the ligand for the purification of a specific antibody Fab fragment.
Other examples are peptides conjugated to drugs for targeted delivery.